Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a ...

Accelerate CGT developement with strategic viral vector manufacturing and CDMO partnerships that balance quality, cost, and ...

OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the CDMO ...

The MarketWatch News Department was not involved in the creation of this content. RANCHO CORDOVA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced the successful CGMP ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...

Oxford Biomedica (LON:OXB) outlined a year of revenue growth, a return to operating EBITDA profitability, and continued ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...

With demand for viral vectors far exceeding supply, manufacturers are rushing to fill the void. Count French CDMO Yposkesi among them. On Tuesday, the five-year-old company unveiled a plan to build a ...

Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

The recent surge in interest in genetically-modified therapies has resulted in a steep rise in demand for different vectors for fundamental and pharmacological research, opening up opportunities for ...

A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...